[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Gugnani MK, Pierson C, Vanderheide R, Girgis RE: Pulmonary edema complicating prostacyclin therapy in pulmonary hypertension associated with scleroderma: a case of pulmonary capillary hemangiomatosis. Arthritis Rheum; 2000 Mar;43(3):699-703
MedlinePlus Health Information. consumer health - Scleroderma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary edema complicating prostacyclin therapy in pulmonary hypertension associated with scleroderma: a case of pulmonary capillary hemangiomatosis.
  • Continuous intravenous infusion of prostacyclin is an effective treatment for primary pulmonary hypertension (PPH), and has recently been shown to be of benefit in PH associated with scleroderma (SSc).
  • Pulmonary capillary hemangiomatosis (PCH) is a rare cause of PPH.
  • Prostacyclin therapy has been complicated by pulmonary edema in cases of PCH.
  • We describe a case of PH associated with limited SSc, where treatment with prostacyclin was complicated by pulmonary edema.
  • There were no clinical features of PCH prior to initiation of vasodilator therapy, illustrating the potential difficulty in establishing the diagnosis.
  • [MeSH-major] Epoprostenol / therapeutic use. Hypertension, Pulmonary / complications. Hypertension, Pulmonary / drug therapy. Pulmonary Edema / complications. Scleroderma, Systemic / complications


2. Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ: Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol; 2006 Oct 3;48(7):1433-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
  • OBJECTIVES: This study evaluated the safety and efficacy of inhaled treprostinil as add-on therapy to oral bosentan in patients with pulmonary arterial hypertension (PAH).
  • BACKGROUND: The addition of a long-acting prostacyclin analogue via the inhaled route might be a safe and effective strategy to optimize therapy in PAH patients on bosentan.
  • METHODS: Twelve patients with symptomatic PAH despite bosentan received either 30 microg of inhaled treprostinil 4 times daily (n = 6) or 45 microg 4 times daily (n = 6), via an ultrasonic nebulizer.
  • RESULTS: One patient was excluded from analysis due to the subsequent finding of pulmonary capillary hemangiomatosis.
  • [MeSH-major] Antihypertensive Agents / administration & dosage. Epoprostenol / analogs & derivatives. Hypertension, Pulmonary / drug therapy. Sulfonamides / administration & dosage
  • [MeSH-minor] Administration, Inhalation. Administration, Oral. Adult. Aged. Blood Pressure / drug effects. Female. Humans. Lung / blood supply. Male. Middle Aged. Severity of Illness Index. Treatment Outcome. Vascular Resistance / drug effects


3. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol; 2009 Jun 30;54(1 Suppl):S43-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of a clinical classification of pulmonary hypertension (PH) is to group together different manifestations of disease sharing similarities in pathophysiologic mechanisms, clinical presentation, and therapeutic approaches.
  • This subgroup includes patients with PAH with a family history or patients with idiopathic PAH with germline mutations (e.g., bone morphogenetic protein receptor-2, activin receptor-like kinase type 1, and endoglin).
  • Finally, it was decided to place pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis in a separate group, distinct from but very close to Group 1 (now called Group 1').
  • [MeSH-major] Hypertension, Pulmonary / drug therapy
  • [MeSH-minor] Algorithms. Anticoagulants / therapeutic use. Antihypertensive Agents / administration & dosage. Calcium Channel Blockers / therapeutic use. Comorbidity. Endothelin Receptor Antagonists. Epoprostenol / administration & dosage. Evidence-Based Medicine. Humans. Prognosis. Randomized Controlled Trials as Topic. Scleroderma, Systemic / epidemiology. Treatment Outcome

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2884-5 [24794121.001]
  • [CommentIn] J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2883-4 [24794126.001]
  • [CommentIn] J Am Coll Cardiol. 2010 Jan 19;55(3):267; author reply 267 [20117425.001]
  • (PMID = 19555858.001).
  • [ISSN] 1558-3597
  • [Journal-full-title] Journal of the American College of Cardiology
  • [ISO-abbreviation] J. Am. Coll. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antihypertensive Agents; 0 / Calcium Channel Blockers; 0 / Endothelin Receptor Antagonists; DCR9Z582X0 / Epoprostenol
  • [Number-of-references] 57
  •  go-up   go-down


Advertisement
4. Wananukul S, Voramethkul W, Nuchprayoon I, Seksarn P: Diffuse Neonatal Hemangiomatosis: report of 5 cases. J Med Assoc Thai; 2006 Aug;89(8):1297-303
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse Neonatal Hemangiomatosis: report of 5 cases.
  • Diffuse Neonatal Hemangiomatosis (DNH) is a rare, life-threatening condition associated with a few to hundreds of small, cutaneous and visceral hemangiomas.
  • Response to prednisolone in these cases was not good, one died and four required second line therapy.
  • [MeSH-major] Angiomatosis / diagnosis. Angiomatosis / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Hemangioma / diagnosis. Hemangioma / drug therapy. Liver Neoplasms / diagnosis. Liver Neoplasms / drug therapy. Prednisolone / therapeutic use. Skin Neoplasms / diagnosis. Skin Neoplasms / drug therapy. Vinblastine / therapeutic use

  • Genetic Alliance. consumer health - Diffuse Neonatal Hemangiomatosis.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17048444.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


5. Gottschling S, Schneider G, Meyer S, Reinhard H, Dill-Mueller D, Graf N: Two infants with life-threatening diffuse neonatal hemangiomatosis treated with cyclophosphamide. Pediatr Blood Cancer; 2006 Feb;46(2):239-42
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two infants with life-threatening diffuse neonatal hemangiomatosis treated with cyclophosphamide.
  • Diffuse neonatal hemangiomatosis (DNH) is a rare, frequently fatal disorder characterized by multiple cutaneous and visceral hemangiomas.
  • We were able to stop treatment after 3-4 courses of cyclophosphamide in both infants because of the excellent response.
  • Cyclophosphamide seems to be a safe and effective treatment in patients suffering from life-threatening DNH unresponsive to corticosteroids.
  • [MeSH-major] Angiomatosis / drug therapy. Antineoplastic Agents, Alkylating / administration & dosage. Cyclophosphamide / administration & dosage. Hemangioma / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Disseminated Intravascular Coagulation / etiology. Drug Resistance, Neoplasm / drug effects. Female. Heart Diseases / etiology. Humans. Infant, Newborn. Male. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Diffuse Neonatal Hemangiomatosis.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2006 Dec;47(7):972-3 [16609951.001]
  • (PMID = 16369922.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


6. Pérez-Valle S, Peinador M, Herraiz P, Saénz P, Montoliu G, Vento M: Vincristine, an efficacious alternative for diffuse neonatal haemangiomatosis. Acta Paediatr; 2010 Feb;99(2):311-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vincristine, an efficacious alternative for diffuse neonatal haemangiomatosis.
  • Diffuse neonatal haemangiomatosis (DNH) is an uncommon condition characterized by multiple cutaneous and visceral haemangiomas frequently causing severe complications.
  • Corticosteroids constitute the first therapeutic line; however, when they fail, other alternatives are available, provided possible side effects are closely monitored during and after treatment.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Hemangioma / drug therapy. Liver Neoplasms / drug therapy. Neoplasms, Multiple Primary / drug therapy. Skin Neoplasms / drug therapy. Vincristine / therapeutic use
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Drug Resistance, Neoplasm. Humans. Infant, Newborn. Liver / enzymology. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20353500.001).
  • [ISSN] 1651-2227
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine
  •  go-up   go-down


7. Ho V, Krol A, Bhargava R, Osiovich H: Diffuse neonatal haemangiomatosis. J Paediatr Child Health; 2000 Jun;36(3):286-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse neonatal haemangiomatosis.
  • A newborn girl with severe diffuse neonatal haemangiomatosis is described.
  • [MeSH-minor] Adrenal Cortex Hormones / administration & dosage. Central Nervous System Venous Angioma / diagnosis. Central Nervous System Venous Angioma / drug therapy. Drug Therapy, Combination. Fatal Outcome. Female. Humans. Infant, Newborn. Interferon-alpha / administration & dosage. Magnetic Resonance Imaging. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10849236.001).
  • [ISSN] 1034-4810
  • [Journal-full-title] Journal of paediatrics and child health
  • [ISO-abbreviation] J Paediatr Child Health
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


8. Takahashi A, Ogawa C, Kanazawa T, Watanabe H, Suzuki M, Suzuki N, Tsuchida Y, Morikawa A, Kuwano H: Remission induced by interferon alfa in a patient with massive osteolysis and extension of lymph-hemangiomatosis: a severe case of Gorham-Stout syndrome. J Pediatr Surg; 2005 Mar;40(3):E47-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission induced by interferon alfa in a patient with massive osteolysis and extension of lymph-hemangiomatosis: a severe case of Gorham-Stout syndrome.
  • The treatment of massive osteolysis with lymphangioma and/or hemangioma (Gorham-Stout syndrome) has been controversial.
  • The authors report on a patient with multiple massive osteolyses and extensive lymph-hemangiomatosis whose lesions were reduced by interferon alfa therapy.
  • There were also hemangiomas in the liver and spleen, a tumor lesion in the left lower chest wall, and hemangiomatous change on the skin surface of the left back.
  • After steroid pulse therapy, pericardial effusion disappeared.
  • During these treatments, the 7th to 10th ribs disappeared from the x-ray and scoliosis developed.
  • One month later, a cloudy fluid collection in the right lung was found on computed tomography.
  • Interferon alfa and steroid pulse therapy were started.
  • Later, the progress of osteolysis and the extension of lymph-hemangiomatosis stopped.
  • The interferon alfa therapy was stopped 14 months after it was administered.
  • At this time, computed tomography shows regression of the hemangiomatous lesion in the back.
  • The authors clinically diagnosed the patient as having Gorham-Stout syndrome with extension of lymph-hemangiomatosis.
  • Interferon alfa with or without steroid therapy should be a choice for patients with extension lesions.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Interferon-alpha / therapeutic use. Osteolysis, Essential / drug therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Antineoplastic Agents / therapeutic use. Child, Preschool. Chylothorax / etiology. Drug Therapy, Combination. Female. Femur / pathology. Hemangioma / drug therapy. Humans. Liver Neoplasms / drug therapy. Lymphangioma / complications. Lymphangioma / drug therapy. Neoplasms, Multiple Primary / drug therapy. Picibanil / therapeutic use. Pleural Effusion / etiology. Pulmonary Atelectasis / etiology. Remission Induction. Ribs / pathology. Scoliosis / etiology. Skin Neoplasms / drug therapy. Spine / pathology. Splenic Neoplasms / drug therapy. Syndrome. Thoracic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793714.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Interferon-alpha; 39325-01-4 / Picibanil
  •  go-up   go-down


9. Hurvitz SA, Hurvitz CH, Sloninsky L, Sanford MC: Successful treatment with cyclophosphamide of life-threatening diffuse hemangiomatosis involving the liver. J Pediatr Hematol Oncol; 2000 Nov-Dec;22(6):527-32
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with cyclophosphamide of life-threatening diffuse hemangiomatosis involving the liver.
  • A female neonate with diffuse hemangiomatosis and hepatic hemangiomas had cardiac insufficiency develop and had failure to thrive.
  • She is now 6-years-old, well-developed, and has no signs of hepatomegaly, malnourishment, or heart failure.
  • Cyclophosphamide appears to be a safe, effective, and rapid treatment of life-threatening hemangiomas of infancy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Cyclophosphamide / therapeutic use. Hemangioma / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Failure to Thrive / etiology. Female. Heart Failure / etiology. Humans. Infant, Newborn. Magnetic Resonance Imaging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11132222.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  • [Number-of-references] 45
  •  go-up   go-down


10. Bonifazi E, Acquafredda A, Milano A, Montagna O, Laforgia N: Severe hypoglycemia during successful treatment of diffuse hemangiomatosis with propranolol. Pediatr Dermatol; 2010 Mar-Apr;27(2):195-6
Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe hypoglycemia during successful treatment of diffuse hemangiomatosis with propranolol.
  • A 27-day-old male infant with diffuse hemangiomatosis of the skin and liver was treated with oral propranolol at a dosage of 2 mg/kg per day.
  • Although the risk appears small, increased vigilance for hypoglycemia in children on chronic propranolol treatment who have decreased caloric intake for any reason seems prudent.
  • [MeSH-major] Hemangioma / drug therapy. Hypoglycemia / chemically induced. Liver Neoplasms / drug therapy. Propranolol / adverse effects. Propranolol / therapeutic use
  • [MeSH-minor] Energy Intake. Humans. Infant, Newborn. Ketone Bodies / blood. Magnetic Resonance Imaging. Male. Skin Neoplasms / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20537072.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ketone Bodies; 9Y8NXQ24VQ / Propranolol
  •  go-up   go-down


11. Ginns LC, Roberts DH, Mark EJ, Brusch JL, Marler JJ: Pulmonary capillary hemangiomatosis with atypical endotheliomatosis: successful antiangiogenic therapy with doxycycline. Chest; 2003 Nov;124(5):2017-22
Hazardous Substances Data Bank. DOXYCYCLINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary capillary hemangiomatosis with atypical endotheliomatosis: successful antiangiogenic therapy with doxycycline.
  • We report here our experience in achieving remission in a 20-year-old man with pulmonary capillary hemangiomatosis (PCH) with atypical endotheliomatosis following therapy with doxycycline.
  • The patient's symptoms, lung function, and radiographic findings had worsened despite treatment with both prednisone and alpha-interferon.
  • Following several weeks of therapy, a gradual resolution of symptoms was noted, with normalization of pulmonary function test results and urine bFGF levels.
  • After 18 months of therapy, the patient remains in complete remission.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Doxycycline / therapeutic use. Hemangioma, Capillary / drug therapy. Lung / pathology. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14605083.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Matrix Metalloproteinase Inhibitors; 103107-01-3 / Fibroblast Growth Factor 2; N12000U13O / Doxycycline
  •  go-up   go-down


12. Vlahovic A, Simic R, Djokic D, Ceran C: Diffuse neonatal hemangiomatosis treatment with cyclophosphamide: a case report. J Pediatr Hematol Oncol; 2009 Nov;31(11):858-60
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse neonatal hemangiomatosis treatment with cyclophosphamide: a case report.
  • We present 3-month-old male infant with diffuse neonatal hemangiomatosis.
  • Computed tomography scan revealed the presence of hemangiomas in the liver and kidneys; laryngobronchoscopy identified the presence of hemangioma in tracheobronchial tree.
  • Treatment with corticosteroids, in dose of 3 mg/kg/d intravenously, was initiated.
  • After 3 years of follow-up the child is well developed, fully recovered, without cardiologic or respiratory problems.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Cyclophosphamide / administration & dosage. Hemangioma / drug therapy. Hemangioma / pathology. Mesna / administration & dosage. Protective Agents / administration & dosage

  • Genetic Alliance. consumer health - Diffuse Neonatal Hemangiomatosis.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19829152.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Protective Agents; 8N3DW7272P / Cyclophosphamide; NR7O1405Q9 / Mesna
  •  go-up   go-down


13. Mazereeuw-Hautier J, Hoeger PH, Benlahrech S, Ammour A, Broue P, Vial J, Ohanessian G, Léauté-Labrèze C, Labenne M, Vabres P, Rössler J, Bodemer C: Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr; 2010 Aug;157(2):340-2
Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis.
  • No side-effects of the drug were noted.
  • [MeSH-major] Hemangioma / drug therapy. Liver Neoplasms / drug therapy. Propranolol / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Female. Heart Failure / prevention & control. Humans. Infant. Male. Treatment Outcome. Vasodilator Agents / therapeutic use

  • Genetic Alliance. consumer health - Diffuse Neonatal Hemangiomatosis.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20488455.001).
  • [ISSN] 1097-6833
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Vasodilator Agents; 9Y8NXQ24VQ / Propranolol
  •  go-up   go-down


14. Schiavetti A, De Pasquale MD, Di Salvo S, Ventriglia F, Clerico A: Recombinant interferon alfa 2a in hepatic hemangiomatosis with congestive heart failure: a case report. Pediatr Hematol Oncol; 2003 Mar;20(2):161-5
Hazardous Substances Data Bank. FUROSEMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recombinant interferon alfa 2a in hepatic hemangiomatosis with congestive heart failure: a case report.
  • The therapy with subcutaneous interferon-alfa-2a (IFN-alpha) was administered for 12 months with progressive regression of cutaneous hemangiomas, liver lesions, and cardiological alterations.
  • IFN-alpha therapy was effective without any significant adverse effects.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Heart Failure / etiology. Hemangioma / drug therapy. Interferon-alpha / therapeutic use. Liver Neoplasms / drug therapy
  • [MeSH-minor] Abdominal Neoplasms / congenital. Abdominal Neoplasms / drug therapy. Digitalis Glycosides / therapeutic use. Diuretics / therapeutic use. Dyspnea / etiology. Female. Furosemide / therapeutic use. Head and Neck Neoplasms / congenital. Head and Neck Neoplasms / drug therapy. Heart Septal Defects, Atrial / complications. Heel. Hemangioma, Capillary / congenital. Hemangioma, Capillary / drug therapy. Hemangioma, Cavernous / congenital. Hemangioma, Cavernous / drug therapy. Hepatomegaly / etiology. Humans. Infant. Knee. Neoplasms, Multiple Primary / congenital. Neoplasms, Multiple Primary / drug therapy. Recombinant Proteins. Remission Induction

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12554528.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Digitalis Glycosides; 0 / Diuretics; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; 7LXU5N7ZO5 / Furosemide
  •  go-up   go-down


15. Glade RS, Vinson K, Becton D, Bhutta S, Buckmiller LM: Management of complicated hemangiomas with vincristine/vinblastine: Quantitative response to therapy using MRI. Int J Pediatr Otorhinolaryngol; 2010 Nov;74(11):1221-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of complicated hemangiomas with vincristine/vinblastine: Quantitative response to therapy using MRI.
  • PURPOSE: To quantify the efficacy of vincristine and vinblastine in the treatment of complicated hemangiomas.
  • Only patients who received both a pre and post-treatment magnetic resonance imaging (MRI) were considered.
  • A database was created which includes patient gender, age at treatment initiation, rationale for treatment, hemangioma location, number of cycles of chemotherapy received, and complications of treatment.
  • A single pediatric radiologist calculated lesion volumes from both pre and post-treatment MRI which were compared to quantify treatment response.
  • Mean age at treatment initiation was 20 weeks (median 14, range 5-60).
  • Rationale for treatment included four patients (57%) with proptosis/orbital compromise and one patient each (14%) with heart failure, airway compression, and hemangiomatosis with rapid growth of multiple lesions.
  • Patients received a mean of 2.86 cycles of chemotherapy (median 3, range 1-5).
  • Twelve lesions were identified and analyzed for pre and post-treatment volume on MRI in the seven patients.
  • Eleven of twelve (92%) lesions decreased in size after treatment.
  • The mean volume ratio of hemangiomas at the conclusion of chemotherapy was 0.45 compared to pre-treatment size (median 0.18, range 0-2.19) Orbital compromise, airway compression, and cardiac failure either improved or resolved in all patients.
  • Three complications of treatment were seen in seven patients (42%) including bacteremia with anemia, peripheral neuropathy and motor delay.
  • All complications resolved after cessation of chemotherapy.
  • CONCLUSIONS: Treatment of complicated hemangiomas with vincristine or vinblastine can control growth and improve symptoms in the majority of patients.
  • Treatment often requires multiple cycles of chemotherapy.
  • Complications of treatment are common, but reversible.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Hemangioma / drug therapy. Hemangioma / pathology. Vincristine / therapeutic use
  • [MeSH-minor] Anemia / etiology. Bacteremia / etiology. Developmental Disabilities / etiology. Facial Neoplasms / drug therapy. Facial Neoplasms / pathology. Female. Humans. Infant. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Magnetic Resonance Imaging. Male. Peripheral Nervous System Diseases / etiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ireland Ltd.
  • (PMID = 20884067.001).
  • [ISSN] 1872-8464
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine
  •  go-up   go-down


16. Bongiorno MR, Aricò M: Preliminary communication: imiquimod in mixed capillary/lymphatic malformation. Dermatol Ther; 2008 Oct;21 Suppl 2:S39-42
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After 4 weeks of therapy the lesions were less protuberant.
  • At the follow-up examination after a further 2 months of therapy, there was partial clinical regression of the capillary component with a return to normal skin color.
  • One month after termination of therapy the lesions had completely regressed and there was no evidence of recurrence of the hemangiomatous section.
  • The present authors' case suggests the efficacy of the use of topical imiquimod and this therapeutic modality may be of particular benefit in superficial type of capillary/lymphatic malformation, in which the destructive intervention may be undesirable.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Facial Neoplasms / drug therapy. Hemangioma / drug therapy. Lymphatic Abnormalities / drug therapy
  • [MeSH-minor] Adolescent. Capillaries / abnormalities. Capillaries / drug effects. Chin. Humans. Lymphatic Vessels / abnormalities. Lymphatic Vessels / drug effects. Male

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837733.001).
  • [ISSN] 1529-8019
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


17. Al-Sebeih K, Manoukian J: Systemic steroids for the management of obstructive subglottic hemangioma. J Otolaryngol; 2000 Dec;29(6):361-6
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present 14 patients with subglottic hemangioma treated between 1984 and 1997,4 of whom had associated extralaryngeal hemangiomatous lesions (28%).
  • There were no major complications from the systemic steroid treatment.
  • One patient developed a cushingoid face that was reversed after the cessation of steroid therapy.
  • [MeSH-major] Airway Obstruction / drug therapy. Anti-Inflammatory Agents / therapeutic use. Dexamethasone / therapeutic use. Hemangioma / drug therapy. Laryngeal Neoplasms / drug therapy. Prednisolone / therapeutic use
  • [MeSH-minor] Child, Preschool. Drug Administration Schedule. Female. Humans. Infant. Male

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Choking.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11770144.001).
  • [ISSN] 0381-6605
  • [Journal-full-title] The Journal of otolaryngology
  • [ISO-abbreviation] J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


18. Collins A: Experience with anti-angiogenic therapy of giant cell granuloma of the facial bones. Ann R Australas Coll Dent Surg; 2000 Oct;15:170-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience with anti-angiogenic therapy of giant cell granuloma of the facial bones.
  • It was first used in 1989 in the management of a child with pulmonary haemangiomatosis.
  • Kaban reported on anti-angiogenic therapy of a recurrent giant cell tumour of the mandible in a 5 year old girl with interferon alfa-2a reasoning that as it was a rapidly proliferating vascular lesion it could be treated as an haemangioma.
  • This paper reviews the history and role of interferon alfa-2a as an angiogenesis inhibitor in the treatment of complex haemangiomas and presents its use in the successful management of a rapidly growing central giant cell granuloma in a 4 year old boy in Australia.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Granuloma, Giant Cell / drug therapy. Interferon-alpha / therapeutic use. Mandibular Diseases / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11709933.001).
  • [ISSN] 0158-1570
  • [Journal-full-title] Annals of the Royal Australasian College of Dental Surgeons
  • [ISO-abbreviation] Ann R Australas Coll Dent Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Interferon-alpha; 0 / Recombinant Proteins; 103107-01-3 / Fibroblast Growth Factor 2; 76543-88-9 / interferon alfa-2a
  • [Number-of-references] 7
  •  go-up   go-down


19. Montani D, Savale L, Natali D, Jaïs X, Herve P, Garcia G, Humbert M, Simonneau G, Sitbon O: Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J; 2010 Aug;31(15):1898-907
MedlinePlus Health Information. consumer health - Pulmonary Hypertension.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: The response to acute vasodilator testing [>20% decrease in mean pulmonary artery pressure (mPAP) and total pulmonary resistance] was assessed in 663 consecutive PAH patients with connective tissue disease (CTD; n = 168), portal hypertension (PoPH; n = 153), anorexigen use (n = 127), human immunodeficiency virus infection (HIV; n = 124), congenital heart disease (CHD; n = 50), and pulmonary veno-occlusive disease or capillary haemangiomatosis (PVOD/PCH; n = 41).
  • All patients with a long-term CCB response were alive after 5 years; two deaths not related to PAH occurred after this time.
  • [MeSH-major] Antihypertensive Agents / therapeutic use. Appetite Depressants / adverse effects. Calcium Channel Blockers / pharmacology. Hypertension, Pulmonary / drug therapy. Vasodilator Agents / pharmacology
  • [MeSH-minor] Adult. Aged. Female. Humans. Long-Term Care. Male. Middle Aged. Pulmonary Artery / physiopathology. Vascular Resistance / drug effects. Vasodilation / drug effects. Young Adult


20. Enjolras O, Brevière GM, Roger G, Tovi M, Pellegrino B, Varotti E, Soupre V, Picard A, Leverger G: [Vincristine treatment for function- and life-threatening infantile hemangioma]. Arch Pediatr; 2004 Feb;11(2):99-107
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vincristine treatment for function- and life-threatening infantile hemangioma].
  • [Transliterated title] Traitement par vincristine des hémangiomes graves du nourrisson.
  • AIM: To evaluate the efficacy of vincristine treatment for function- and life-threatening hemangiomas.
  • PATIENTS AND METHOD: Nine infants, eight girls and one boy, received vincristine treatment (VCR) for endangering hemangiomas.
  • In six cases, the hemangiomas involved head and neck in a segmental unilateral or bilateral distribution (3/6 also had laryngeal and 2/6 tracheal location causing respiratory distress, 5/6 had eyelid and orbital involvement); one infant had disseminated neonatal hemangiomatosis (skin, liver, kidney); two infants had liver hemangiomas with cardiac failure.
  • VCR was prescribed after failure of high-dosage corticosteroid treatment in six, and of both corticosteroids and interferon alpha 2b (5 months) in one; two infants received VCR as first line treatment.
  • The nine infants received from 5 to 25 injections (average: 16), for a length of treatment of 1.5-8 months (average: 5.5 months).
  • In seven patients a clear clinical response was observed at the end of the first month of treatment, while a slow protracted response was noted in two.
  • DISCUSSION: Corticosteroid treatment, although a worldwide recognized treatment of problematic hemangiomas, cannot always control the growth of alarming hemangiomas.
  • Interferon alpha 2a and 2b have proven a 90% effectiveness: treatment for cortico-resistant, function- and life-threatening, hemangiomas.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Hemangioma / drug therapy. Skin Neoplasms / drug therapy. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14761730.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine
  •  go-up   go-down


21. Yu DC, Grabowski MJ, Kozakewich HP, Perez-Atayde AR, Voss SD, Shamberger RC, Weldon CB: Primary lung tumors in children and adolescents: a 90-year experience. J Pediatr Surg; 2010 Jun;45(6):1090-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A wide range of histopathologic tumor types occurs.
  • This study aims to determine the incidence of different primary lung tumors in children and to contribute data leading to the development of evidence-based treatment models.
  • RESULTS: Forty patients were identified (23 boys, 17 girls) with a mean age of 9.6 years (range, 3 months to 19 years).
  • Fourteen distinct histopathologic tumor types were identified.
  • The most common tumor types were carcinoid (8), inflammatory myofibroblastic tumor (7), and pleuropulmonary blastoma (6).
  • Rare pediatric lung tumors including small cell carcinoma, adenocarcinoma, and pulmonary capillary hemangiomatosis were also seen.
  • Chemotherapy was used in 23% (9) and radiation in 20% (8) of the patients.
  • Of the 33 survivors, 28 had follow-up with a median duration of 29.5 months (mean, 63.2 months; range, 1-471 months).
  • The tumor spectrum involves many types not seen in adults, and unlike adults, patients rarely have a history of exposure to external predisposing factors.
  • Although complete resection remains the standard for treatment of most tumors, addition of adjuvant therapy is dependent on both tumor stage and histopathologic type.
  • [MeSH-minor] Adolescent. Age Distribution. Child. Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Infant. Male. Morbidity / trends. Prognosis. Retrospective Studies. Sex Distribution. Survival Rate / trends. Time Factors. United States / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20620301.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Metry DW, Hebert AA: Benign cutaneous vascular tumors of infancy: when to worry, what to do. Arch Dermatol; 2000 Jul;136(7):905-14
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To discuss the current knowledge regarding complicated hemangiomas (cervicofacial, periorbital, lumbosacral, and parotid), including the associated syndromes of diffuse neonatal hemangiomatosis and PHACES (posterior fossa malformations, most commonly of the Dandy-Walker variant; hemangiomas [especially large, plaquelike, facial lesions]; arterial anomalies; cardiac anomalies and coarctation of the aorta; eye abnormalities; and sternal cleft and/or supraumbilical raphe).
  • To discuss the risks and benefits of current treatment options, including the use of systemic corticosteroids and interferon in necessary situations.
  • Dermatologists should also be aware of available treatment options, including the use of systemic chemotherapy in life-threatening situations.
  • [MeSH-minor] Abnormalities, Multiple. Hemangioendothelioma / congenital. Hemangioendothelioma / diagnosis. Hemangioendothelioma / pathology. Hemangioendothelioma / therapy. Humans. Infant. Infant, Newborn. Syndrome

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10890993.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


23. Isaacs H Jr: Fetal and neonatal hepatic tumors. J Pediatr Surg; 2007 Nov;42(11):1797-803
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this review is to focus on the fetus and neonate in an attempt to determine the various ways liver tumors differ clinically and pathologically from those found in the older child and adult and to show that certain types of tumors have a better prognosis than others.
  • There were 76 (65%) examples of solitary (unifocal) hemangiomas and 41 (35%) of multifocal (which included the entity diffuse hemangiomatosis) with 86% and 71% survival rates, respectively.
  • There was some relationship between histologic type and prognosis.
  • Fifteen of 32 hepatoblastoma patients received surgical resection with or without chemotherapy, resulting in 7 (47%) of 15 cures.
  • Pre- or postoperative chemotherapy is reserved for those patients with unresectable tumors or metastatic disease.

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18022426.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


24. Liu C, Chen J: Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev; 2006;(3):CD004434
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (3) PAH associated with collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, HIV infection, drugs and toxins or other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, splenectomy);.
  • (4) PAH associated with significant venous or capillary involvement, which includes pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH);.
  • AUTHORS' CONCLUSIONS: ERAs in conjunction with conventional therapy over 12 to 16 weeks can improve exercise capacity, Borg dyspnoea scores and several cardiopulmonary haemodynamics variables in patients mainly with idiopathic PAH.
  • The data on mortality do not currently show a benefit of this class of drugs on this endpoint.
  • [MeSH-major] Antihypertensive Agents / therapeutic use. Endothelin Receptor Antagonists. Hypertension, Pulmonary / drug therapy
  • [MeSH-minor] Humans. Isoxazoles / therapeutic use. Randomized Controlled Trials as Topic. Sulfonamides / therapeutic use. Thiophenes / therapeutic use


25. Le Luyer B, Duquenoy A, Poinsot J, Boulloche J, Gaussin G, Le Roux P: [Use of interferon in a case of hepatic hemangioma]. Arch Pediatr; 2000 Nov;7(11):1201-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After failure of classic therapies, and when surgery or arterial embolization are not possible, those benign tumours may benefit from interferon alpha treatment.
  • CASE REPORT: We report a case of a 14-month-old infant who presented with hepatic hemangiomatosis and cardiac failure.
  • The disease can neither be controlled by steroids nor by radiotherapy associated with digitalo-diuretic treatment.
  • CONCLUSION: Interferon alpha treatment helps to control cardiac failure and the course of hepatic hemangioma in childhood.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hemangioendothelioma / drug therapy. Interferon-alpha / therapeutic use. Liver Neoplasms / drug therapy
  • [MeSH-minor] Female. Humans. Infant. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11109948.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] FRANCE
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


26. Agnese M, Cipolletta L, Bianco MA, Quitadamo P, Miele E, Staiano A: Blue rubber bleb nevus syndrome. Acta Paediatr; 2010 Apr;99(4):632-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endoscopy is the gold standard technique for the diagnosis of BRBNS with GI lesions and also allows immediate therapeutic measures such as argon plasma coagulation, laser photocoagulation, sclerotherapy or band ligation.
  • In addition, pharmacological treatments based on corticosteroids, interferon alfa, vincristine or octreotide have been described for BRBNS.
  • CONCLUSION: Blue Rubber Bleb Nevus Syndrome is a congenital cutaneous and gastrointestinal haemangiomatosis.
  • The treatment is based on pharmacological or surgical therapy.

  • Genetic Alliance. consumer health - Nevus.
  • Genetic Alliance. consumer health - Blue Rubber Bleb Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958301.001).
  • [ISSN] 1651-2227
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


27. Meyer L, Graffstaedt H, Giest H, Truebenbach J, Waner M: Effectiveness of propranolol in a newborn with liver hemangiomatosis. Eur J Pediatr Surg; 2010 Nov;20(6):414-5
Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of propranolol in a newborn with liver hemangiomatosis.
  • [MeSH-major] Cardiovascular Agents / therapeutic use. Hemangioma / drug therapy. Liver Neoplasms / drug therapy. Propranolol / therapeutic use

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20628969.001).
  • [ISSN] 1439-359X
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cardiovascular Agents; 9Y8NXQ24VQ / Propranolol
  •  go-up   go-down


28. Jarvi K, Roebuck DJ, Sebire NJ, Lindley K, Shah N, Salomon J, Curry JI: Successful treatment of extensive infantile hemangiomatosis of the small bowel in a 3-month-old with thalidomide and somatostatin analog. J Pediatr Gastroenterol Nutr; 2008 May;46(5):593-7
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of extensive infantile hemangiomatosis of the small bowel in a 3-month-old with thalidomide and somatostatin analog.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Hemangioma / drug therapy. Intestinal Neoplasms / drug therapy. Somatostatin / analogs & derivatives. Thalidomide / therapeutic use
  • [MeSH-minor] Female. Humans. Infant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18493217.001).
  • [ISSN] 1536-4801
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide; 51110-01-1 / Somatostatin
  •  go-up   go-down






Advertisement